Subscribe

DCI Blog

All
All

Duke Cancer Institute (DCI) Blog provides updates, organizational announcements, the latest in funding opportunities and information on upcoming conferences and symposiums. This blog also highlights inspiring patient stories and the accomplishments and achievements of DCI faculty and staff. Subscribers are invited to submit story ideas and other news of interest. Email submissions and feedback to Karen E. Butler, Director of Communications, Duke Cancer Institute.

Florida Golf Tournament Raises $50,000 For Brain Tumor Research

Jacksonville, Florida, resident Oren Margol loved nothing more than getting out with his buddies for a game of golf. In fact, he and his friends eventually formed an informal once-a-year tourney they deemed, in good humor, the “Catholics Versus the Jews.” And although it was admittedly a little lop...

Duke Team Finds Missing Immune Cells That Could Fight Lethal Brain Tumors

Glioblastoma brain tumors can have an unusual effect on the body’s immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body’s defenses. Where the T-cells go has been unclear, even as immunotherapies are increasingly employed to stimulate the body’s...

Poliovirus Therapy for Recurrent Glioblastoma Has Three-Year Survival Rate of 21 Percent

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. Comparatively, just four percent of patients at Duke with...

Newly Identified Genetic Markers Classify Previously Undetermined GBM Tumors

Most glioblastoma tumors are marked by one or two broad mutation patterns, but about 20 percent of the lethal brain tumors have biomarkers that cannot be identified. Now scientists at Duke Cancer Institute have identified mutations for the vast majority of the remaining 20 percent of...

Brain Tumor Center Names New Director

David M. Ashley, PhD, was recently named director of The Preston Robert Tisch Brain Tumor Center. He succeeds Darell Bigner, MD, PhD, who became director emeritus on Feb. 1. Before leaving Australia to join Duke in 2017 as professor of neurosurgery and director of the pediatric neuro-oncology...

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed  

A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases, researchers at the Duke Cancer Institute...

Charging the Bull: Brain Tumor Survivor Never Surrenders

If 43-year-old Gabe Stewart were a matador, he would likely be a bull’s worst enemy. Just ask his wife of 19 years, Tera, or his two kids, a 13-year-old daughter and an 11-year-old son — they’ll testify to his stubborn refusal to be beaten, no matter what the odds. On May 3, 2010, Stewart was...

Tumor-Seeking Salmonella Treats Brain Tumors

Biomedical engineers at Duke University have recruited an unlikely ally in the fight against the deadliest form of brain cancer — a strain of salmonella that usually causes food poisoning. Clinicians sorely need new treatment approaches for glioblastoma, the most aggressive form of brain cancer...

Duke’s Poliovirus Therapy Wins “Breakthrough” Status

The recombinant poliovirus therapy developed at the Preston Robert Tisch Brain Tumor Center at Duke Health has been granted “breakthrough therapy designation” from the U.S. Food and Drug Administration. The designation will expedite research into the poliovirus therapy, but it does not mean the...

Tune To CBS This Sunday Evening

As reported Thursday night, May 12, on CBS Evening News with Scott Pelley, 60 Minutes will update viewers on new developments in Duke's poliovirus therapy for glioblastoma, including the news that the research was granted “breakthrough” status by the FDA to speed development.

Kwatra Receives NIH/NCATS Award

In July NCATS announced nearly $3 million to fund cooperative agreements with four academic research groups to conduct pre-clinical validation studies, clinical feasibility studies or proof-of-concept clinical trials to test whether the selected assets may be effective against a previously...